)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Anika Therapeutics (ANIK) investor relations material
Anika Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary30 Jul, 2025
Executive summary
Regenerative Solutions revenue grew 41% year-over-year, led by Integrity Implant System, which exceeded 2024 performance and is on pace to more than double in 2025.
Q2 2025 revenue was $28.2M, down 8% year-over-year, mainly due to OEM channel declines and manufacturing issues.
Hyalofast Phase III trial missed co-primary endpoints but achieved significance on key secondary endpoints; FDA submission remains on track, with commercial launch now expected in 2027.
Strategic focus shifted to OA Pain Management and Regenerative Solutions, with divestitures of Arthrosurface and Parcus Medical completed.
Production yield issues resolved by June, with full production resumed and no impact on patient supply.
Financial highlights
Gross margin for Q2 2025 was 51%, down from 67% year-over-year, impacted by a $3M one-time charge for lower yields.
Adjusted EBITDA was negative $0.2M, a significant decline year-over-year, mainly due to one-time scrap costs and lower high-margin revenue.
Operating expenses declined 17% year-over-year, with SG&A down 22% and R&D down 6%.
Cash and cash equivalents at June 30, 2025, totaled $53.2M, with no outstanding debt.
Adjusted diluted loss per share for Q2 2025 was ($0.13); loss from continuing operations was ($4.6M).
Outlook and guidance
2025 commercial channel revenue expected at $47M–$49.5M (12%–18% growth); OEM channel at $62M–$65M (16%–20% decline).
Adjusted EBITDA guidance for 2025 remains at -3% to +3%.
Commercial channel growth outlook revised to 10%–20% for 2026 and 2027 due to Hyalofast launch delay; $3M Hyalofast revenue expected in 2027.
Focus remains on expanding OA Pain Management and Regenerative Solutions portfolios, including U.S. launches pending regulatory approval.
Cingal program advanced toward NDA filing, with bioequivalence study initiation expected by year-end.
Explain the revised long-term revenue guidance.
Discuss the impact of production yield issues.
Detail Integrity's growth and expansion plans.
How did COVID impact Hyalofast trial data?
Assess OEM partnership diversification progress.
Will Integrity & Hyalofast boost gross margin?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Anika Therapeutics earnings date
Q3 202530 Oct, 2025
Next Anika Therapeutics earnings date
Q3 202530 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Anika Therapeutics Inc. is a medical technology company focused on developing, manufacturing, and commercializing products for joint health and orthopedic applications. The company's offerings include therapeutic solutions for pain management, joint preservation, and tissue repair, utilizing proprietary hyaluronic acid-based technology and other advanced biomaterials. Anika serves healthcare providers, including orthopedic surgeons and clinicians, with a portfolio that addresses conditions such as osteoarthritis and soft tissue injuries. The company is headquartered in Bedford, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage